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Abstract  66 
Nonprimate hepacivirus (NPHV), the closest homolog of hepatitis C virus (HCV) described to 67 
date, has recently been discovered in horses. Even though both viruses share a similar genomic 68 
organization, conservation of the encoded hepaciviral proteins remains undetermined. The HCV 69 
p7 protein is localized within endoplasmic reticulum (ER) membranes and is important for 70 
production of infectious particles. In this study, we analyzed the structural and functional features 71 
of NPHV p7 in addition to its role during virus assembly. Three-dimensional homology models 72 
for NPHV p7 by using various NMR structures were generated highlighting conserved residues 73 
important for ion-channel function. By applying a liposome permeability assay, we observed that 74 
NPHV p7 exhibited similar liposome permeability features than HCV p7 indicative of similar 75 
ion-channel activity. Next, we characterized the viral protein using a p7-based trans-76 
complementation approach. A similar sub-cellular localization pattern at the ER membrane was 77 
observed, although production of infectious particles was likely hindered by genetic 78 
incompatibilities with HCV proteins. To further characterize these cross-species constraints, 79 
chimeric viruses were constructed by substituting different regions of HCV p7 with NPHV p7. 80 
The N-terminus and transmembrane domains were non-exchangeable and therefore constitute a 81 
cross-species barrier in hepaciviral assembly. In contrast, the basic loop and the C-terminus of 82 
NPHV p7 were readily exchangeable allowing production of infectious trans-complemented viral 83 
particles. In conclusion, comparison of NPHV and HCV p7 revealed structural and functional 84 
homology of these proteins including liposome permeability and broadly acting determinants 85 
were identified which modulate hepaciviral virion assembly and contribute to the host-species 86 
barrier.  87 
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Importance 88 
The recent discovery of new relatives of hepatitis C virus (HCV) enables for the first time the 89 
study of cross-species determinants shaping hepaciviral pathogenesis. Nonprimate hepacivirus 90 
(NPHV) was described to infect horses and represents so far the closest homolog of HCV. Both 91 
viruses encode the same viral proteins; however NPHV protein functions remain poorly 92 
understood. In this study, we aimed to dissect NPHV p7 on a structural and functional level. By 93 
using various NMR structures of HCV p7 as templates, three-dimensional homology models for 94 
NPHV p7 were generated highlighting conserved residues being important for ion-channel 95 
function. A p7-based trans-complementation approach and the construction of NPHV/HCV p7 96 
chimeric viruses showed that the N-terminus and transmembrane domains were non-97 
exchangeable. In contrast, the basic loop and the C-terminus of NPHV p7 were readily 98 
exchangeable allowing production of infectious viral particles. These results identify species-99 
specific constraints as well as exchangeable contaminants in hepaciviral assembly. 100 
101 
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Introduction 102 
For more than two decades, hepatitis C virus (HCV) and GB virus B (GBV-B) were the sole 103 
members of the genus Hepacivirus within the Flaviviridae family. Recently, multiple new 104 
hepaciviruses have been identified in dogs (1), horses (2), bats (3, 4), rodents (3, 5), non-human 105 
primates (6), rats (7) and cattle (8, 9). Among them, nonprimate hepacivirus (NPHV), initially 106 
described to infect dogs and subsequently horses, is the closest homolog of HCV and thus 107 
represents a unique model to study differences in hepacivirus pathogenesis of HCV and HCV-108 
related viruses (10, 11). 109 
HCV is globally distributed and approximately 146 million people of the world’s population are 110 
persistently infected (12). Individuals infected with HCV are at high risk of developing liver 111 
cirrhosis and hepatocellular carcinoma (13). The development of direct-acting antivirals (DAA’s) 112 
has significantly improved antiviral treatment options (14). However, a prophylactic vaccine is 113 
still lacking. The genome of HCV consists of a single-stranded RNA with positive polarity and 114 
encodes for ten viral proteins in an open reading frame (ORF) (15). The small membrane protein 115 
p7 is encoded between the structural proteins core, E1 and E2 and the non-structural proteins. P7 116 
is classified into the group of viroporins since it fulfills major characteristics of this family for 117 
instance its small size of 63 amino acids and its ability to form oligomeric, hydrophobic ion-118 
channels in the endoplasmic reticulum (ER) membrane (16). P7 is composed of two 119 
transmembrane passages connected by a short polar loop. The N-terminal helix and C-terminus 120 
are facing towards the lumen of the ER (17), however another topology where the C-terminus is 121 
exposed towards the cytosol has also been reported (18). P7 monomers assemble to form 122 
hexameric or heptameric structures (19-22). By applying single-particle electron microscopy a 123 
three-dimensional model of a p7 hexamer was resolved (20). Additionally, the monomeric and 124 
oligomeric structure of p7 of different genotypes was elucidated by nuclear magnetic resonance 125 
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spectroscopy (NMR) studies in different lipid-mimicking environments (TFE, DHPC, DPC or 126 
methanol) (23-26), which likely explains the structural discrepancies observed between these 127 
models. In vitro analysis revealed that p7 is essential for HCV assembly and release, whereas it is 128 
dispensable for viral replication (27, 28). For further details on structural and functional 129 
properties of HCV p7 see also recent reviews (16, 29, 30). 130 
After the identification of NPHV, several studies have been conducted to investigate differences 131 
and similarities between NPHV and HCV. A high seroprevalence of anti-NPHV antibodies (30-132 
40%) among horses was reported with 2-7% of the horses also carrying viral RNA (10). Similar 133 
to HCV, also NPHV is a hepatotropic virus as was evidenced by accumulation of viral plus and 134 
minus strand RNA in liver sections (31). The genomic organization of HCV and NPHV is highly 135 
conserved with one ORF encoding the viral proteins (10, 11). As seen for HCV, the ORF of 136 
NPHV is flanked by two untranslated regions (UTR) at the 5’ and 3’ end with the 5’UTR 137 
displaying a larger stem loop I (2). Regarding the function of NPHV viral proteins, individual 138 
expression of the NPHV core protein showed that core localizes on lipid droplets as reported for 139 
HCV core (32). In addition, the NS3/4A protein of NPHV has been shown to have a similar 140 
function as the HCV equivalent by cleaving human mitochondrial antiviral signaling protein 141 
(MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing interferon-beta (TRIF) (33). 142 
However, a detailed understanding of viral protein function especially in the context of cross-143 
species determinants shaping hepaciviral pathogenesis is lacking. 144 
In this study, we discovered that although NPHV p7 shared comparable structural features with 145 
its human homolog and exerted an ion-channel activity, the protein could not fully substitute 146 
HCV p7 during virus assembly. Replacement of the basic loop and the C-terminus within NPHV 147 
p7, however, led to production of infectious HCV particles, thus defining virus species-specific 148 
and interchangeable subdomains within p7. 149 
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Materials and Methods 150 
Sequence and phylogenetic analysis. Nucleotide sequences of NPHV p7 isolates (GenBank 151 
Accession numbers: KP325401, JQ434002, JQ434003, JQ434004, JQ434005, JQ434006, 152 
JQ434007, JQ434008, JX948116; generated p7 sequences of this study are available upon 153 
request) were translated and aligned using MEGA6 (34) and a consensus sequence was 154 
generated. For phylogenetic analysis one representative p7 sequence of each HCV genotype was 155 
utilized (GenBank Accession numbers: NC004102, YP001469630, NC009824, NC009825, 156 
NC009826, NC009827, EF108306). The HCV p7 consensus sequence was deduced from the 157 
ClustalW multiple alignment (35) of p7 sequences from representative HCV strains of confirmed 158 
genotypes (as described in reference (23)). A Maximum Likelihood phylogenetic tree was 159 
generated using MEGA6 (34).   160 
 161 
Structural analysis. Three-dimensional homology models of NPHV p7 monomer were 162 
constructed by the Swiss-Model automated protein structure homology modeling server 163 
(http://www.expasy.org/spdbv/; (36)) by using the NMR structures of HCV p7 as templates (23-164 
26). Two models of the NPHV p7 three-dimensional hexamer were generated. The positions of 165 
models 1 and 2 relatively to the membrane bilayer was deduced from molecular dynamics (MD) 166 
simulations of HCV p7 in POPC bilayer as reported in Chandler et al. (19) and Kalita et al. (37), 167 
respectively. Figures were generated from structure coordinates by using VMD 168 
(http://www.ks.uiuc.edu/Research/vmd/; (38)) and rendered with POV-Ray 169 
(http://www.povray.org/). 170 
 171 
Peptide synthesis of HCV and NPHV p7. The p7 peptides of the JFH-1 or H14 strain were 172 
synthesized with a CEM microwave peptide synthesizer. Therefore, all required amino acids were 173 
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dissolved in N,-N,-dimethylformamide (DMF; Rathburn Chemicals Ltd). As activator 174 
hydroxybenzotriazole (HoBt) hydrate and as activator base N,N’-diisopropylcarbodiimide (DIC; 175 
Sigma) were used. Deprotection was conducted in 20% piperidine (Sigma) in DMF (v/v). 176 
Dichlormethane (Sigma) was used for washing. 16.4 l of DMF, 150 ml of activator, 200 ml of 177 
activator base, 2.8 l of deprotect, 0.17 g of resin and 0.2 M of each respective amino acid were 178 
placed in a CEM microwave peptide synthesizer and a programme was created to start synthesis 179 
from the C-terminus. The first amino acid added was arginine (Arg), since alanine (Ala) is 180 
attached to the resin. Reactions for all the amino acids were double coupling except proline. 181 
Cycles for Arg, Cys and His are performed at lower temperature and for a longer time period to 182 
avoid racemization. To avoid any side chain reaction only Fmoc-Lys (Boc)-OH for lysine (Lys) 183 
was used with double coupling. The instrument will automatically stop and collect the resin with 184 
synthesized peptide which is then required to cleave the peptide from resin. Peptides were 185 
purified by HPLC on a C4-semipreparative column with a linear acetonitrile gradient. The purity 186 
was verified by SDS PAGE. The sequence of the p7 peptide was confirmed by MALDI-TOF 187 
mass spectromic analysis.  188 
 189 
Liposome permeability assay. Liposome preparation and permeability assays were conducted as 190 
described earlier (39). Briefly, lipids (Avanti Polar Lipids) in chloroform were added in a final 191 
mixture containing 0.5 mg L-α-phosphatidic acid, 0.5 mg L-α-phosphatidyl choline and 0.5 % 192 
w/w L-α-phosphatidyl ethanolamine with lissamine rhodamine B labelled head groups. 193 
Chloroform was evaporated from the lipids using a stream of nitrogen, before placing in a 194 
vacuum for 4 hours at room temperature (RT). Lipids were rehydrated to 2 mg/ml in a self-195 
quenching concentration of carboxyfluorescein (CF) buffer (50 mM 5(6)-Carboxyfluorescein 196 
(SIGMA), 10 mM HEPES (pH 7.4), 107 mM NaCl) and vigorously shaken overnight at RT. 197 
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Unilamellar liposomes were produced using an extruder (Avanti Polar Lipids) and a 0.4 µm filter 198 
(whatman). Liposomes were purified via centrifugation at 49 000 rpm for 15 min at 25°C 199 
including 4 washing steps before the pellet was resuspended in 0.5 ml liposome assay buffer (10 200 
mM HEPES, pH 7.4, 107 mM NaCl).  For p7 activity assays the peptides were reconstituted in 201 
100% DMSO and the concentration was determined by nanodrop. Liposomes supplemented with 202 
1% v/v DMSO were used as a baseline for fluorescence. Assays were carried out in black-walled, 203 
flat-bottomed black-base 96-well plates at 37°C. Each well contained 50 µM of liposomes 204 
(calculated from the rhodamine fluorescence) and 1 µl of peptide in DMSO in a total volume of 205 
100 µl with liposome assay buffer. 0.5 % v/v Triton TX-100, which lyses liposomes, was used 206 
for gain adjustment, setting a level of 90% fluorescence. The 96-well plate was kept on ice for 2-207 
5 minutes after gain adjustment and while the peptide +/- drug was added. CF release measured 208 
by increased fluorescence was taken as an indicator of peptide induced membrane permeability 209 
(activity). A set of 30 readings (λ ex485/ λem520 nm) was made over the course of 24 minutes 210 
using a FLUOstar Galaxy plate-reader (BMG Labtech). Each condition was carried out in 211 
duplicate wells with three independent experimental repeats. End point measurements were used 212 
for the analysis with the average of the duplicate wells taken. For NN-DNJ inhibition assays 213 
liposomes contained 2% v/v DMSO +/- 40 µM NN-DNJ, these being the respective background 214 
levels for drug-free and drug-treated wells. As peptide concentrations 9 µM of NPHV p7 peptide 215 
and 44 µM of JFH-1 p7 peptide were used. Peptides +/- inhibitor were incubated for 20 minutes 216 
at RT prior to addition to the gain adjusted plate on ice. Statistical analysis was conducted by a 217 
Welch’s corrected unpaired t-test. P-values <0.05 were considered as statistical significant (*). 218 
 219 
Cell culture. Huh-7.5 cells were cultured in Dulbecco’s modified Eagle’s medium (Life 220 
Technologies) supplemented with 10 % fetal bovine serum (FCS), 2 mM L-glutamine, 221 
11 
 
nonessential amino acids (Invitrogen), 100 µg/ml streptomycin (Invitrogen) and 100 IU/ml 222 
penicillin (Invitrogen) (DMEM complete) at 37°C and 5% CO2. The packaging cell line Huh-223 
7.5[C][E1E2][NS2]J6 expressing the Jc1 derived proteins C, E1E2 and NS2 was generated by 224 
lentiviral gene transfer as described earlier (40). Vectors used for the gene transfer encoded for a 225 
blasticidin-S deaminase resistance gene and therefore 5 µg/ml of blasticidin (Invivogen) was 226 
added for selection. 227 
 228 
Plasmids. The plasmids and pFK-PI-Spp7/J6-EI-NS3-5B/JFH-1, pFK-PI-Sp-HA-HA-L-p7/J6EI-229 
NS3-5B/JFH-1 and pFK-PI-G-Luc-EI-NS3-5B/JFH-1 have been described earlier (41, 42) and 230 
are based on the bicistronic helper replicon pFK-PI-EI-NS3-5B/JFH-1. This helper replicon 231 
contains a poliovirus derived internal ribosomal entry site (IRES) (PI) downstream of the JFH-1 232 
derived 5’-nontranslated region (5’NTR) (nucleotides 1 to 341 of JFH-1) and is separated by a 233 
spacer region of 72 nucleotides. The second cistron is under the control of an 234 
encephalomyocarditis virus IRES (EI) that expresses JFH-1 derived NS3 to NS5B proteins. The 235 
p7 sequence of the NPHV isolate H14 and different HCV/NPHV p7 chimeras were chemically 236 
synthesized (Integrated DNA Technologies, IDT). The cloned fragments included a signal 237 
peptide (sp) derived from the last 51 base pairs of the E2 protein (HCV isolate J6) downstream of 238 
the p7 sequence or additionally a HAHA-tag linked to the p7 sequence with a linker and upstream 239 
of the sp. The respective genes were cloned into the first cistron of pFK-PI-EI-NS3-5B/JFH-1 by 240 
restriction digest and ligation. In addition to bicistronic helper replicons used for trans-241 
complementation assays, experiments with the HCV full length virus were also performed. 242 
Therefore the plasmids pFK-Jc1 (43), pFK-Jc1-Δp7half (27) and pFK-Jc1-HA-HA-L-p7/J6 (42) 243 
were utilized. The p7 sequence of the NPHV isolate H14 and the p7 sequences of HCV/NPHV 244 
chimeras (p7J6-loop-H14, p7J6-C-ter-H14 and p7J6-loop-C-ter-H14) were cloned into pFK-Jc1 245 
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and pFK-Jc1-HA-HA-L-p7/J6 by polymerase chain reaction (PCR)-based insertion. All 246 
constructs were confirmed by sequencing prior to use. Further details regarding the cloning 247 
strategies and exact nucleotide sequences are available upon request. 248 
 249 
In vitro transcription and electroporation. In vitro transcripts were created according to the 250 
protocol described previously (40). DNA was purified by the Qiaquick PCR purification kit 251 
(Qiagen) and RNA was purified by the NucleoSpin RNA Extraction Kit (Macherey Nagel) 252 
according to the manufacturer’s instructions. Concentration was determined by nanodrop. In vitro 253 
transcribed RNA was stored at -80°C until electroporation.  254 
Electroporations were conducted as described earlier (40). Briefly, Huh-7.5 or Huh-255 
7.5[C][E1E2][NS2]J6 cells were trypsinized, taken up in DMEM complete and the cell number 256 
was determined. A final concentration of 1.5x107 cells/ml in 400 µl of Cytomix (120 mM KCl, 257 
0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4 (pH 7.6), 25 mM HEPES, 2 mM EGTA, 5 mM 258 
MgCl2, adjust pH to 7.6 with KOH) supplemented with 2 mM ATP and 5 mM Glutathione per 259 
electroporation and 5-10 µg of in vitro transcripts were used per electroporation. Transfected 260 
cells were directly taken up in 12-16 ml DMEM complete and seeded into 6-well plates or 10 cm 261 
dishes depending on the application.   262 
 263 
Immunofluorescence. After transfection, cells were seeded into a 24-well plate onto coverslips. 264 
Cells were fixed 48 h post transfection by addition of 3% paraformaldehyde. Staining of 265 
intracellular HAHA-tagged p7 and a co-staining of E2 or NS3 was performed as described 266 
elsewhere (42).  In brief, fixed cells were permeabilized with 0.5% Triton-X100 for 10 minutes at 267 
RT. Blocking was conducted for one hour at RT in blocking buffer (5% goat serum (Sigma) in 268 
PBS). The primary antibodies were incubated overnight at room temperature in blocking buffer. 269 
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The primary mouse α-HA antibody (Covance) was diluted 1:1000, the primary rabbit α-NS3 270 
4949 (44) was diluted 1:400 and the primary human α-E2 antibody CBH-23 (45) was diluted 271 
1:250 in blocking buffer. The α-NS3 and α-E2 antibodies were kind gifts from R. Bartenschlager 272 
(University of Heidelberg) and S. Foung (Stanford University), respectively. Species-specific 273 
secondary antibodies (A488-conjugated α-mouse IgG, A546-conjugated α-rabbit IgG and A546-274 
conjugated α-human IgG) were diluted 1:1000 in blocking buffer and incubated for 1 hour at RT 275 
in the dark. Cell nuclei were stained with DAPI (Invitrogen). Last, coverslips were mounted on 276 
glass slides using Fluoromount-G (Southern Biotech). Pictures were taken using a x100 277 
magnification lens by an inverted confocal laser-scanning microscope (Olympus Fluoview 1000). 278 
A sequential acquisition mode with an average of 3 frames for each picture (Kalman n=3) was 279 
applied for the 3 channels used. 280 
 281 
Western blot. Western blot analysis of cell lysates was performed as previously described (42). 282 
Briefly, cells were lysed 48 h post transfection by addition of 1% Trition-X100 supplemented 283 
with protease inhibitor (Roche). Nuclei were separated by centrifugation and reducing sample 284 
buffer was added to the supernatant. Samples were incubated at 37°C for 15 minutes prior 285 
separation by SDS-PAGE. After transfer of the separated proteins on a membrane, the membrane 286 
was incubated for 1 h in blocking solution (5% milk in 0.05% Tween/PBS). The primary 287 
antibody was incubated over night at 4°C in blocking solution. The following dilutions were used 288 
for the antibodies: mouse α-HA (Sigma) 1:1000; mouse α-NS5A 9E10 (46) 1:1000; mouse α-289 
NS2 6H6 (47) 1:1000; mouse α-E2 AP33 1:1000; mouse α-βactin (Sigma) 1:1000. The α-NS5A 290 
9E10 and α-NS2 6H6 antibodies were a generous gift from C. M. Rice (Rockefeller University). 291 
The α-E2 AP33 antibody was provided by Genentech and Arvind Partel (University of Glasgow) 292 
(48). The secondary horseradish peroxidase-conjugated (HRP)-coupled antibody (α-mouse, 293 
14 
 
Sigma) was incubated for 1 h at room temperature. It was diluted 1:20 000 except after 294 
incubation with the α-HA antibody (1:2000). After washing in 0.05% Tween/PBS, 295 
chemiluminescence was obtained with the ECL Plus Western Blotting Detection System (GE 296 
Healthcare) and measured using a ChemoCam Imager. 297 
 298 
Virus titration. To determine viral titers in collected supernatants, a limiting dilution assay was 299 
conducted on Huh-7.5 cells. The 50% tissue culture infectious dose (TCID50) was determined 72 300 
h post infection as reported earlier (40). 301 
  302 
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Results 303 
NPHV p7 amino acid sequence is highly conserved and shows structural features 304 
comparable to HCV p7 305 
To examine the degree of p7 amino acid sequence conservation among different NPHV p7 306 
isolates, 15 distinct NPHV p7 sequences were aligned and a consensus sequence was generated 307 
(Fig. 1A). The identification of the respective NPHV p7 sequences was based on cleavage site 308 
predictions as reported earlier (11). Overall, the NPHV p7 sequences were highly conserved at 309 
the amino acid level with only 11 positions (over the 63 residues) showing some variations (Fig. 310 
1A). Alignment of globally sampled NPHV and HCV p7 nucleotide sequences and subsequent 311 
phylogenetic analysis revealed a high level of divergence between HCV and NPHV, with each 312 
virus forming a discrete, well supported clade (Fig. 1B). Of note, sampled NPHV p7 isolates 313 
showed a remarkably lower nucleotide variation when compared to HCV p7 isolates derived 314 
from genotypes (GT) 1-7, which is indicated by the different branch lengths (Fig. 1B). Database 315 
searching for proteins related to NPHV p7 using either Blast (49) or Fasta (50) revealed that p7 316 
from HCV genotype 4f displays the highest similarity to the NPHV consensus sequence, with 317 
33% of identical amino acids and 28% and 13% of strongly and weakly similar amino acids. 318 
Moreover, similar percentages were observed when comparing the NPHV p7 consensus sequence 319 
with p7 consensus sequences from representative HCV strains of confirmed genotypes (51, 52) 320 
(19% identical, 24% strongly similar, 16% weakly similar and 30% different residues; Fig. 2A). 321 
With respect to the non-conserved residues, one can distinguish those exhibiting obvious 322 
physicochemical differences (colored dark blue in Fig. 2A) from those for which the hydrophobic 323 
or hydrophilic character is conserved (colored light blue). Moreover, most of the latter NPHV p7 324 
residues could be observed as minor variants in the p7 amino acid repertoire of HCV reference 325 
genotypes (reported in Fig. 2A in (27); residue positions 11, 22, 37, 44, 45 and 51). In total, only 326 
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20% of residue positions distributed along the sequence appeared to be clearly specific for NPHV 327 
and HCV p7, including positions 1, 5, 7, 9, 13, 14, 16, 29, 33, 39, 43, 46 and 47. Altogether, 328 
these data indicate that the overall structure of NPHV p7 should be comparable to that of HCV 329 
p7. This was also supported by secondary structure analyses and predictions of transmembrane 330 
segments, which exhibited similar patterns for NPHV and HCV p7 (data not shown).  331 
Several NMR structures have been reported for HCV p7 (19, 23-26) allowing us to construct 332 
three-dimensional homology structure models for NPHV p7 by using the Swiss-Model automated 333 
protein structure homology modeling server (http://www.expasy.org/spdbv/; (36)) and the 334 
consensus NPHV p7 sequence as input. The four resulting homology structure models for the 335 
monomeric form of NPHV p7 are depicted in Figure 2B. The three first models exhibited a 336 
“hairpin-like” topology consisting of two transmembrane segments that are connected by a 337 
hydrophilic, positively charged cytosolic loop containing residues 33 and 35. According to the 338 
corresponding hexameric forms of these models (19, 24, 25) and to the typical oligomeric 339 
structure of viroporins (53), NPHV p7 subunits would reside side-by-side as illustrated by model 340 
1 in Figure 2C. In contrast, NPHV p7 homology model based on the NMR structure of hexameric 341 
p7 reported by Ouyang et al. (26) would exhibit an unusual architecture where part of each p7 342 
subunit crosses over to interact with other p7 subunits that are not its neighbors (model 2, Fig. 343 
2C). Nevertheless, these models allowed the positioning of conserved, very similar, similar, 344 
different and very different residues (colored from red to blue, respectively) along the secondary 345 
structure elements for each model (Fig. 2B) as well as at the surface of hexamer models and 346 
within their ion-channel pores (Fig. 2C).  347 
 348 
NPHV p7 exerts an ion-channel activity in a liposome permeability assay 349 
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As the NPHV p7 structural analyses revealed similar features to HCV p7, we next used the 350 
liposome permeability assay previously reported for HCV p7 (39) to evaluate its ion-channel 351 
features. To produce the respective p7 peptides of NPHV (isolate H14) and HCV (isolate JFH-1), 352 
a chemical synthesis was performed (see Material and Methods). The p7 peptides were 353 
reconstituted in DMSO and validated using mass spectrometry and SDS-PAGE, before 354 
increasing doses of the peptides were incubated with liposomes previously loaded with 355 
carboxyfluorescein (CF) at self-quenching concentrations . In this assay, increase in membrane 356 
permeability was measured by the dye release and dequenching. An increase of fluorescence was 357 
observed when the NPHV p7 peptide was added to the liposomes, which reached a plateau with a 358 
peptide concentration of 10-20 µM (Fig. 3A). The HCV JFH-1-derived peptide demonstrated an 359 
ion-channel activity in a dose-dependent manner with about 2-3-fold higher fluorescent units 360 
(FU) compared to NPHV p7 (Fig. 3B). As the iminosugar derivative N-nonyl-deoxynojirimycin 361 
(NN-DNJ) was reported to block the HCV p7 ion-channel activity (54), we analyzed the 362 
inhibitory effect of NN-DNJ against NPHV p7. As depicted in Figure 3C, NPHV p7-dependent 363 
permeabilization of liposomes could be blocked with 40 µM NN-DNJ in a similar fashion as 364 
HCV p7 (Fig. 3C). Taken together, similar to HCV p7, these data indicate that NPHV p7 is likely 365 
able to exert an ion-channel function which can be blocked by iminosugar derivatives.  366 
 367 
Cross-species substitutions of the basic loop and the C-terminus in p7 lead to production of 368 
trans-complemented particles 369 
To study the capability of NPHV p7 to rescue production of infectious particles, we made use of 370 
a p7-based HCV trans-complementation system (41). This system permits the evaluation of p7 371 
function in virus-producing cells independently of secondary effects on polyprotein processing. 372 
The p7 sequence originating from the NPHV isolate H14 was cloned into the first cistron of a 373 
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bicistronic JFH-1 helper replicon (Fig. 4A). The p7 sequence was located downstream of a signal 374 
peptide (sp) sequence encompassed within the last 51 amino acids of the HCV E2 protein derived 375 
from the J6 isolate. Additionally and to facilitate p7 detection, another construct containing a sp, 376 
HAHA-tag and a short linker sequence (GGGGSG) connected to NPHV p7 H14 was created. The 377 
analogous constructs containing HCV p7 of the isolate J6 or the Gaussia-Luciferase gene (G-378 
Luc), both previously described (41, 42), were utilized as positive and negative controls, 379 
respectively. The second cistron encoded for the non-structural proteins NS3-NS5B from the 380 
HCV isolate JFH-1. In vitro transcripts of these constructs were individually transfected into a 381 
packaging cell line encoding for the remaining viral proteins, core (C), E1E2 and NS2 from the 382 
HCV isolates J6 and JFH-1 (Fig. 4A). To confirm the expression of HAHA-tagged p7, we 383 
performed Western blot analysis showing that both HAHA-tagged p7 J6 and HAHA-tagged p7 384 
H14 were expressed (Fig. 4B). However, in the lysate of HAHA-tagged p7 H14 additional 385 
proteins with a higher molecular weight were detected (Fig. 4B) indicating SDS-resistant 386 
oligomeric forms of the HAHA-tagged p7. Next, we analyzed the sub-cellular localization of 387 
HAHA-tagged p7 in fixed cells by indirect fluorescence microscopy using antibodies recognizing 388 
the HA-tag, HCV NS3 or E2 proteins in order to permit the assessment of co-localization 389 
between these polypeptides (Fig. 4C). Both HAHA-tagged p7 proteins, J6 and H14, showed a 390 
similar localization in the cytoplasm at ER membranes by co-localizing with E2 and NS3. The 391 
rescue of HCV particle production by NPHV p7 was assessed after transfection of the packaging 392 
cell line with the different p7 variants and infectivity released into the cell culture supernatant of 393 
transfected cells. The J6-derived p7 construct could be rescued with peak titers of 5x104 394 
TCID50/ml, while the double HA-tagged genome produced lower viral progeny as previously 395 
reported (42). In contrast, NPHV p7 (with or without epitope tag) could not substitute the HCV 396 
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p7 function in this trans-complementation setting suggesting genetic incompatibilities between 397 
NPHV p7 and HCV proteins.  398 
To explore if NPHV p7 and HCV p7 contain virus-specific but potentially also interchangeable 399 
(thus functionally conserved) subdomains, we replaced parts of HCV p7 with sequences of 400 
NPHV p7. To this end, we constructed eleven distinct chimeras by dividing p7 into the N-401 
terminal, transmembrane helix 1 (TM1), basic loop, transmembrane helix 2 (TM2) and C-402 
terminal subdomain (Fig. 5A). All chimeric constructs were N-terminally tagged with a double 403 
HA-tag connected by a short linker and preceded by a signal peptide sequence. These sequences 404 
were cloned into the first cistron of a bicistronic JFH-1 helper replicon and in vitro transcripts 405 
were transfected into Huh-7.5[C][E1E2][NS2]J6 packaging cells analogous to Figure 4A. 406 
Expression of HAHA-tagged p7 variants was assessed by immunofluorescence analysis showing 407 
the expression of chimeras 1, 2, 3, 5 and 11 and low or undetectable expression for the remaining 408 
constructs (Fig. 5B) indicating an early degradation or a general incompatibility between HCV p7 409 
and NPHV p7 parts. Next, we investigated the capability of these p7 chimeras to trans-410 
complement the production of infectious particles. The p7 chimeras 3 (replacement of the loop, 411 
subsequently termed p7J6-loop-H14), 5 (replacement of the C-terminus, subsequently termed 412 
p7J6-C-ter-H14) and 11 (replacement of the loop and C-terminus, subsequently termed p7J6-413 
loop-C-ter-H14) were able to produce infectious particles (Fig. 5C). Viral titers of about 1-2 414 
orders of magnitude lower compared to p7J6 were observed with p7J6-C-ter-H14 showing the 415 
highest titers. Replacement of the loop decreased the viral titers about 50-fold more drastically 416 
and delayed the virus kinetics. To further examine the functionality of these chimeras, the 417 
bicistronic replicons encoding for p7J6, p7H14, p7J6-loop-H14, p7J6-C-ter-H14 and p7J6-loop-418 
C-ter-H14 N-terminally linked to a signal peptide were co-transfected into Huh-7.5 cells with 419 
Jc1Δp7half, a HCV full length mutant described to completely abrogate viral particle production 420 
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(27) (Fig. 5D). As shown in Figure 5E, p7J6 as well as p7J6-loop-H14, p7J6-C-ter-H14 and p7J6-421 
loop-C-ter-H14 were able to rescue infectious particle production (Fig. 5E). In conclusion, cross-422 
species determinants in the basic loop and the C-terminus of hepaciviral p7 could be identified by 423 
using a p7-based trans-complementation system.  424 
 425 
Cross-species determinants of NPHV p7 are important in late steps of the viral life cycle 426 
After the identification of cross-species determinants in hepaciviral virion production by creating 427 
HCV/NPHV p7 chimeras, we next validated their functionality in the context of full-length HCV 428 
cell culture derived particles (HCVcc). Hence, we cloned p7J6-loop-H14, p7J6-C-ter-H14, p7J6-429 
loop-C-ter-H14 and p7H14 into Jc1 and Jc1 HAHA-L-p7 (Fig. 6A). As positive control we 430 
included the HCV constructs Jc1 and Jc1 HAHA-L-p7J6. These genomes were transfected into 431 
Huh-7.5 cells and expression of epitope-tagged p7 was visualized 48 h later by Western blot 432 
analysis. For the positive control Jc1 HAHA-L-p7J6 HAHA-tagged p7 could be detected as well 433 
as the precursor proteins p7-NS2 and E2-p7-NS2 (Fig. 6B). In case of HAHA-L-p7H14 cleavage 434 
defects were noted with signals at a molecular weight of approximately 24 kDa and 50 kDa 435 
suggesting processing defects due to the insertion of H14 p7 into Jc1 (Fig. 4B). These proteins 436 
were also detected for p7J6-loop-H14 and p7J6-loop-C-ter-H14, but here also free p7 was visible. 437 
The p7J6-C-ter-H14 chimera showed an HA-detection pattern like the parental construct (Fig. 438 
6B) indicating processing defects possibly at the E2/p7 junction or different oligomerization 439 
forms. In addition, Western blot analysis to visualize NS2 and E2 in the same cell lysates was 440 
conducted showing that only the precursor p7NS2 and no free NS2 can be detected for Jc1 441 
HAHA-L-p7H14 (Fig. 6C). 442 
Next, the release of infectious viral particles for the Jc1 constructs (Fig. 6D) and Jc1 HAHA-L-p7 443 
(data not shown) constructs was determined by TCID50 at different time points post transfection. 444 
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All HCV/NPHV epitope-tagged p7 chimeras led to the production of infectious particles while 445 
displaying delayed time kinetics and lower titers compared to Jc1 HAHA-L-p7J6 (data not 446 
shown). Moreover, as reported previously (42), these titers were around one order of magnitude 447 
lower compared to the untagged constructs shown in Figure 6D. Jc1 p7J6-loop-C-ter-H14 448 
showed the lowest production of infectious particles, whereas Jc1 p7H14 was not able to produce 449 
infectious particles, which is in concordance to the results in the trans-complementation system. 450 
As HCV p7 was reported to be important for the assembly and release step of the viral life cycle 451 
(27, 28, 41), we investigated whether this function was also conserved in the context of the p7 452 
chimeric genomes. To this end, we determined extra- and intracellular core amounts 48 h post 453 
transfection (Fig. 6E) and calculated the specific infectivity for each construct (Fig. 6F). The 454 
intracellular core amounts were comparable for all constructs, whereas the recombinant chimeric 455 
constructs displayed a reduction in extracellular levels of core with Jc1 p7H14 at background 456 
levels in line with the results from the infection assay (Fig. 6E). Therefore, the specific infectivity 457 
of Jc1 p7J6-loop-H14 and Jc1 p7J6-C-ter-H14 was comparable to Jc1 demonstrating an 458 
importance of NPHV p7 in viral assembly and release of infectious particles rather than in virus 459 
entry. In case of the Jc1 p7J6-loop-C-ter-H14 the infectivity levels and extracellular core amounts 460 
were minimal, therefore no specific infectivity could be calculated. Taken together, HCV/NPHV 461 
p7 chimeras defining cross-species determinants of virion assembly were functional in the 462 
context of HCV cell culture particles and were crucial for the late steps of the viral life cycle.   463 
 464 
Virion production of HCV/NPHV p7 chimeras can be inhibited by prototypic ion-channel 465 
blockers 466 
Inhibitors including rimantadine and iminosugar derivatives blocking the ion-channel function or 467 
oligomerization of HCV p7 have been described (55), but their detailed mechanism of action is 468 
22 
 
not well defined. To facilitate the understanding of p7 inhibitor functions and evaluate the ion-469 
channel activity of the HCV/NPHV p7 chimeras in the context of the complete viral life cycle, 470 
we next tested the antiviral activity of the prototypic ion-channel inhibitors rimantadine (Fig. 7A) 471 
and two iminosugars N-nonyl-deoxygalactonojirimycin (NN-DGJ) (Fig. 7B) and N-nonyl-472 
deoxynojirimycin (NN-DNJ) (Fig. 7C) against Jc1 p7J6-loop-H14 and Jc1 p7J6-C-ter-H14. 473 
Inhibitors were added to cells 4 h post transfection and viral titers were determined 48 h post 474 
transfection. Jc1 p7J6-loop-H14 was inhibited by rimantadine, NN-DGJ and NN-DGJ to a similar 475 
level as the Jc1 wildtype (Fig. 7A, B and C). In contrast, Jc1 p7J6-C-ter-H14 showed a slightly 476 
higher resistance profile to rimantadine and NN-DGJ compared to the parental Jc1 construct (Fig. 477 
7A and B) indicating a lower binding affinity and less inhibitory activity of these inhibitors when 478 
structural changes occur at the C-terminus of p7. These results indicate that in the context of 479 
HCV/NPHV p7 chimeric viruses functional ion-channels are formed which can be inhibited by 480 
specific p7 inhibitors. 481 
  482 
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Discussion 483 
In this study, we performed a comparison of NPHV and HCV p7 on a structural and functional 484 
level. Sequence alignment of reported and novel p7 isolates revealed a high level of conservation 485 
among all isolates, especially when compared to the variation apparent among HCV isolates. This 486 
is in accordance with the overall high conservation of the full NPHV genome between different 487 
isolates, where a diversity of approximately 15% was reported in contrast to 30% of diversity 488 
between HCV isolates (10). Amino acid sequence similarities indicate that the overall structure of 489 
NPHV p7 is comparable to that of HCV p7, allowing us to construct NPHV p7 homology models 490 
using reported three-dimensional NMR-based HCV p7 structures (19, 23-26) as templates for 491 
monomeric and hexameric models. A greater degree of amino acid identity was found in the C-492 
terminal 48-63 p7 segment, including conservation of the upstream cleavage site of the signal 493 
peptidase at the p7-NS2 junction. Despite the amino acid variability in 37-47 segment when 494 
compared to HCV p7, the overall C-terminal half of p7 NPHV exhibits the characteristic 495 
structural features of a signal peptide (Fig. 2A), and thus likely acts as a signal for the re-496 
initialization of translocation of the C-terminal part of p7. Interestingly, most of the different 497 
residues in this segment are located at the surface of the hexamer homology models, and thus 498 
should not disturb ion-channeling function of p7, but could potentially play a role in p7 499 
interactions with other viral or cellular partners. Additionally, a high degree of amino acid 500 
similarity was found in segment 17-32, which is thought to be the main structural element 501 
involved in p7 pore formation and function. An interesting difference is the presence of only one 502 
basic residue at position 35 in the putative cytosolic loop of NPHV p7 instead of two fully 503 
conserved basic residues at positions 33 and 35 in p7 of all HCV genotypes (17). This suggests 504 
that the basic residue at position 33 in HCV might be not essential for p7 functioning. Moreover, 505 
the N-terminal segment 1-16 exhibited lower similarity with several different residues located 506 
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both at the surface of the hexamer models or facing the pore lumen. These features suggest that 507 
this relatively poorly homologous segment should not play a critical role in ion-channeling but 508 
could be important for specific interactions with other viral and/or host-specific cellular factors. 509 
Moreover, as observed in HCV p7, this N-terminal segment also might play an essential role in 510 
the complex mechanism of E2-p7 processing by signal peptidase (56, 57). Together, all these 511 
structural features indicate a possible ion-channel function of NPHV p7 similar to HCV p7, 512 
which is supported by the results of the liposome permeability assay. For chemically synthesized 513 
p7 peptides of NPHV and HCV an increase of CF release with a concurrent increase of the 514 
peptide concentration was observed. However, due to the property of the NPHV p7 peptide to 515 
form aggregates at high concentrations, the effect was observed at lower peptide concentrations 516 
and at an early peak compared to the HCV p7 peptide. The observed CF release could be blocked 517 
by addition of the iminosugar NN-DNJ indicating an ion-channel function of NPHV p7. The 518 
dibasic motif K33-R35 of HCV p7 was reported earlier to be important to maintain the ion-519 
channel activity in liposomes (58). Importantly and in line with the structural analysis of NPHV 520 
p7, only the basic residue at position 35 is conserved in NPHV p7 and not the basic residue at 521 
position 33, leading to the assumption that specifically residue 35 is essential to preserve p7 522 
function.   523 
We next investigated NPHV p7 determinants specific to NPHV or conserved between HCV and 524 
NPHV.  Moreover, we analyzed its sub-cellular localization and its role in the viral life cycle. By 525 
using a p7-based trans-complementation approach, which is independent of viral polyprotein 526 
processing, we could show that NPHV p7 was successfully expressed despite the detection of 527 
oligomeric forms of NPHV p7. These oligomeric intermediates have not been observed for HCV 528 
p7 so far. Nevertheless, the successful expression of NPHV p7 allowed us to investigate the sub-529 
cellular localization in infected cells. The highest degree of co-localization of HCV p7 with viral 530 
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proteins has been described for E2, whereas also co-localization with NS2, NS3, NS5A and in 531 
parts core were reported (42). This is in accordance with our localization analysis showing that 532 
epitope tagged NPHV p7 co-localizes with NS3 and E2 in a similar pattern as epitope tagged 533 
HCV p7 in the cytoplasm of the cell. Despite the expression of NPHV p7 and sub-cellular 534 
localization similar to HCV p7, no infectious particles were produced in the trans-535 
complementation system probably due to genetic incompatibilities of viral proteins. We could 536 
demonstrate previously that even the replacement of genotype 2a J6-p7 by another HCV isolate 537 
Con1 (genotype 1b) fully abrogated HCV particle production and even replacement by p7 of 538 
another genotype 2a isolate (JFH-1) did significantly reduce the release of infectious particles 539 
(27, 41). To overcome these cross-species genetic incompatibilities, HCV/NPHV p7 chimeras 540 
were constructed demonstrating that the basic cytosolic loop and C-terminus of NPHV p7 as well 541 
as the combination of both are interchangeable between NPHV and HCV thus restoring HCV 542 
infectious particle production. For HCV, inter-genotypic p7 chimeras were also analyzed for 543 
being infectious in vivo when the N-terminal and C-terminal tails of p7 from a genotype 1a virus 544 
were maintained, but other parts substituted by genotype 2a sequences (59). Moreover, we 545 
observed that the basic loop could be substituted without abolishing particle formation underlying 546 
the importance of the basic residue 35 to maintain NPHV p7 functions. Lastly, we tested the 547 
generated chimeras as well as the full NPHV p7 sequence in an HCV full-length virus (HCVcc) 548 
revealing comparable virion production to the trans-complementation system that the complete 549 
NPHV p7 sequence could not compensate for HCV p7 function due to cross-species 550 
incompatibilities. In addition, Western blot analysis showed an absence of mature NPHV p7 with 551 
the correct molecular weight. However, the detected proteins coincide with the molecular weight 552 
of the proteins detected in the trans-complementation system, where no precursor proteins are 553 
produced indicating an oligomerization of NPHV p7 rather than a cleavage defect. Nevertheless, 554 
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the novel chimeras were fully functional and were shown to be important for viral assembly and 555 
release. Thus, virus-specific determinants of hepaciviral virion assembly are located in the N-556 
terminus and transmembrane regions of p7. 557 
Inhibitor experiments with rimantadine and the iminosugar derivatives NN-DGJ and NN-DNJ 558 
were conducted since these prototypic ion-channel inhibitors were reported to target HCV p7 and 559 
reduce particle production (60). These experiments showed that the HCV/NPHV p7 chimera 560 
carrying the C-terminus of NPHV p7 was more resistant especially to rimantadine and NN-DGJ 561 
at high concentrations. The interaction sites of rimantadine with HCV p7 were analyzed 562 
previously (24) showing key interacting residues at position 46, 48 and 52, which are present in 563 
the chimeric construct. However, the change of the C-terminus of p7 could influence the overall 564 
p7 folding, which could compress the rimantadine binding cavity leading to a less favourable fit 565 
for the molecule resulting in a more drug-resistant phenotype. The iminosugar derivative NN-566 
DNJ demonstrated an inhibition of all viruses at the highest concentration, which may results not 567 
only from the p7 ion-channel inhibition, but also from the blockage of ER α-glucosidases 568 
required for folding and maturation of the HCV glycoproteins (60). 569 
In conclusion, the identification of viruses closely related to HCV allowed for the first time a 570 
cross-species comparison of two naturally occurring hepaciviral species. We could show that the 571 
overall structure of NPHV p7 is highly conserved compared to HCV p7 and that NPHV p7 most 572 
likely exhibits an ion-channel activity. Molecular analysis revealed a similar sub-cellular 573 
localization of NPHV p7 with an ER-like pattern. Moreover, although NPHV p7 could not fully 574 
replace HCV p7 function, the basic loop and C-terminus could be substituted leading to the 575 
production of infectious particles. The results implicate a similar role of NPHV p7 in viral 576 
pathogenesis as seen for its human homolog and identify broad hepaciviral protein determinants 577 
for virus assembly. 578 
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Figure legends 581 
Figure 1 582 
Sequence and phylogenetic analysis of NPHV p7. A) Amino acid conservation in NPHV p7. 583 
Top panel represents a sequence logo (61) of the 63 amino acid NPHV p7 ion-channel generated 584 
from an alignment of 15 globally sampled strains (GenBank Accession numbers: KP325401, 585 
JQ434002, JQ434003, JQ434004, JQ434005, JQ434006, JQ434007, JQ434008, JX948116; 586 
generated p7 sequences of this study are available upon request). Nucleotide sequences were 587 
translated and aligned using MEGA6 (34). Individual amino acids are color-coded according to 588 
physiochemical properties and individual residue frequencies in the population are proportional 589 
to the x-axis. The global NPHV p7 consensus sequence is positioned directly below with * 590 
indicating complete conservation at the amino acid level in all sampled strains. B) Phylogenetic 591 
comparison of NPHV and HCV p7. NPHV and HCV p7 nucleotide sequences (189 bp) were 592 
aligned and a Maximum Likelihood phylogenetic tree generated using MEGA6 (34). NPHV p7 593 
sequences represent all available reported sequences downloaded from GenBank, in addition to 594 
sequences generated in this study (GenBank Accession numbers: KP325401, JQ434002, 595 
JQ434003, JQ434004, JQ434005, JQ434006, JQ434007, JQ434008, JX948116, H10, H14-H18). 596 
HCV p7 sequences represent a single isolate from genotypes (GT) 1-7 (GenBank Accession 597 
numbers: NC004102, YP001469630, NC009824, NC009825, NC009826, NC009827, 598 
EF108306). Branch lengths are proportional to the scale bar and equivalent to genetic distance 599 
measured in nucleotide substitutions per site. 600 
 601 
Figure 2 602 
Homology structure models of NPHV p7. A) Comparison of the NPHV p7 consensus sequence 603 
(see also Fig. 1) to HCV p7 consensus sequence. The degree of amino acid physicochemical 604 
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conservation at each position is inferred with the similarity index according to ClustalW 605 
convention (asterix, invariant, red; colon, highly similar, dark pink; dot, similar, pink). Non-606 
conserved but slightly different residues are colored light blue, while very different residues are 607 
colored dark blue. Underlined residues correspond to positions exhibiting conserved aromatic 608 
residues. Positions 33 and 35 in the central cytosolic loop are boxed. Note that the C-terminal 609 
half part of p7 exhibits structural features that are characteristic of signal peptides (62), consisting 610 
of an N-terminal region (n-domain) encompassing 1–3 positively charged residues (Arg), a 611 
hydrophobic core region (h-domain) forming an alpha-helix, and a more polar, flexible region (c-612 
domain) containing a signal peptidase cleavage site; residues at positions -1 and -3 relative to the 613 
cleavage site are small neutral residues (Ala) and form the recognition site for signal peptidases 614 
(63), whereas alpha-helix-destabilizing residues (Pro, Gly) are present at position -6 and/or in the 615 
middle of the h-domain. B) Ribbon representation of the three-dimensional homology models of 616 
NPHV p7 monomer. Four previously published NMR-based structures were used as templates for 617 
modeling (23-26). Left, p7 monomer structure determined by NMR in 50% TFE and molecular 618 
dynamic (MD) simulations ((23); PDB entry); middle left, NMR-based structure of p7 monomer 619 
determined in 125 mM DHPC ((25); PDB entry, 2MTS); middle right, Flag-p7 monomer 620 
structure determined in 100% MeOH ((24); PDB entry, 3ZD0; the Flag tag and C-terminal 621 
extension are not shown); right, one subunit of hexamer p7 NMR structure model determined in 622 
200 mM DPC ((26); PDB entry, 2M6X). N- and C-termini are noted by “N” and “C”, 623 
respectively. Alpha-helical segments are indicated and residues are color-coded according to 624 
panel A. Residues 33 and 35 side-chain atoms are represented as van der Walls spheres and 625 
illustrate the location of the central cytosolic loop of p7. C) Three-dimensional homology models 626 
1 and 2 of NPHV p7 hexamer using the HCV p7 NMR/MD model in POPC of Chandler et al. 627 
((19); model 1) and the HCV p7 NMR model in DPC of Ouyang et al. ((26); model 2) as 628 
30 
 
templates. Two opposing subunits are shown in the left. Hexameric forms of NPHV p7 models 629 
are in surface representations from different viewpoints: middle left, side view of the hexamer 630 
surface; middle right, sectional view showing the pore interior with its axis symbolized by the 631 
dashed line; right, ER lumen view showing the pore. Residues are color-coded according to panel 632 
A and B. Thick green lines shown in the left hand panels represent the polar membrane bilayer 633 
interfaces and hydrophobic core (between the middle two lines).  634 
 635 
Figure 3 636 
Evaluation of the NPHV p7 ion-channel activity in a liposome permeability assay.  The HCV 637 
and NPHV p7 peptides were chemically synthesized and used for subsequent liposome 638 
permeability assays. P7 peptides originating from the A) NPHV isolate H14 and B) HCV isolate 639 
JFH-1 were reconstituted in DMSO. Different concentrations of peptide were added to 50 µM of 640 
carboxyfluorescein loaded liposomes and the fluorescence units [FU] were measured as an 641 
indicator of peptide-induced membrane permeability (activity). Liposomes supplemented with 642 
1% v/v DMSO were used as solvent control. Three independent experiments in duplicate wells 643 
were conducted and mean values +/- SD are depicted. C) Inhibition assays with NN-DNJ were 644 
conducted. Therefore, liposomes contained 2% v/v DMSO +/- 40 µM NN-DNJ, these being the 645 
respective background levels for drug-free and drug-treated wells. As peptide concentrations 9 646 
µM of NPHV p7 peptide and 44 µM of JFH-1 p7 peptide were used. Peptides +/- inhibitor were 647 
incubated for 20 minutes at RT prior to addition to the gain adjusted plate on ice. Three 648 
independent experiments in duplicate wells were conducted. Depicted is the mean value +SD 649 
normalized to the respective solvent control. The percentage of inhibition was calculated by 650 
normalizing to the DMSO control without inhibitor. Statistical analysis was conducted by a 651 
Welch’s corrected unpaired t-test. P-values <0.05 were considered as statistical significant (*). 652 
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 653 
Figure 4 654 
Analysis of NPHV p7 in a trans-complementation setup. A) Experimental setup. The p7 655 
sequence of the HCV isolate J6 and of the NPHV isolate H14 (sequence available upon request) 656 
were cloned either untagged or linked to a HAHA-tag into the first cistron of a bicistronic helper 657 
replicon as previously reported (42). The signal peptide-coding sequence (sp) corresponded to the 658 
last 51 base pairs from the E2 J6 sequence was cloned downstream of p7. The insertion of a 659 
Gaussia luciferase (G-Luc) served as a negative control. The second cistron encodes for the non-660 
structural proteins NS3-NS5B originating from the HCV isolate JFH-1. These bicistronic helper 661 
replicons were individually transfected into a packaging cell line expressing the remaining viral 662 
proteins core (C), E1E2 and NS2 from the HCV isolate J6. B) The expression of HAHA-tagged 663 
p7 in cell lysates was confirmed 48 h post transfection by Western blot analysis. Additionally, the 664 
viral protein NS5A and a cellular protein β-actin were stained. C) Co-staining of NS3 and 665 
HAHA-tagged p7 (upper panel) and of E2 and HAHA-tagged p7 (lower panel) was performed 48 666 
h post transfection on fixed cells. Depicted in gray are single stainings with DAPI, α-HA, α-NS3 667 
and α-E2 as well as a colored merge pictures. Here, cell nuclei are shown in blue, α-HA staining 668 
in green, and α-NS3 and α-E2 are shown in red, respectively. Pictures were taken using a 100x 669 
magnification lens. D) Viral titers in supernatants 24 h, 48 h and 72 h post transfection were 670 
determined by TCID50. The mean of three independent experiments is depicted as log10 671 
TCID50/ml + standard deviation (SD). 672 
 673 
Figure 5 674 
Construction of HCV/NPHV p7 chimeras in a trans-complementation system. A) Eleven 675 
distinct HCV/NPHV p7 chimeras were constructed by dividing p7 into 5 parts (N-terminus, 676 
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transmembrane helix 1 (TM1), loop, transmembrane helix 2 (TM2) and C-terminus, 677 
respectively). As templates the HCV isolate J6 and the NPHV isolate H14 were utilized and their 678 
respective amino acid sequences are depicted. Amino acid sequences originating from H14 are 679 
shown as light gray bars, whereas amino acids originating from J6 are shown as dark gray bars. 680 
P7 chimeras were cloned into the bicistronic helper replicon including a signal peptide, a HAHA-681 
tag and a short linker according to Figure 4A. Constructed bicistronic helper replicons were 682 
transfected into Huh7.5[C][E1E2][NS2]J6 by electroporation. B) Cells were fixed 48 h post 683 
transfection and immunofluorescence analysis by staining for α-HA and DAPI was performed. 684 
Shown are the respective merge pictures with the cell nuclei in blue and the α-HA staining in 685 
green. Pictures were taken with a 100x magnification lens. D) Jc1 Δp7half was co-transfected into 686 
Huh-7.5 cells with in vitro transcribed bicistronic JFH-1 helper replicons encoding for a signal 687 
peptide (sp) downstream of p7J6, p7H14, p7J6-loop-H14, p7J6-C-ter-H14 and p7J6-loop-C-688 
terH14 in the first cistron as well as a G-Luc, respectively. E) Viral titers in supernatants 48 h 689 
post transfection were determined by TCID50 and the mean of three independent experiments is 690 
depicted as log10TCID50 +SD. 691 
 692 
Figure 6 693 
Characterization of HCV/NPHV p7 chimeras in recombinant HCV cell culture viruses. A) 694 
The p7 sequence from the HCV isolate J6 and the NPHV isolate H14 as well as the designated 695 
chimeras were cloned into Jc1 or Jc1 HAHA-L-p7 as depicted. B) In vitro transcripts of the Jc1 696 
HAHA-L-p7 constructs as well as Jc1 wildtype were transfected into Huh-7.5 cells and the 697 
expression of HAHA-tagged p7 in cell lysates was visualized by Western blot analysis 48 h post 698 
transfection. Additionally, the viral protein NS5A and the cellular protein β-actin were stained. 699 
C) Expression of NS2 and E2 in lysates of cells transfected with in vitro transcripts of the Jc1 700 
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HAHA-L-p7 constructs was visualized 48 h post transfection by Western blot analysis. D) Viral 701 
titers of the Jc1 p7 constructs were determined in supernatants 24 h, 48 h and 72 h after 702 
transfection into Huh-7.5 cells. Shown are log10TCID50/ml as mean values of three independent 703 
experiments + SD. E) Intra- and extracellular core amounts were measured 48 h post transfection 704 
of the Jc1 p7 constructs into Huh-7.5 cells. The background level of extracellular core amounts 705 
was set to the upper value of Jc1 p7H14, since this construct does not produce any infectious 706 
particles. Two independent experiments were performed and the mean values +SD as log10 core 707 
fmol/l are shown. F) The specific infectivity was calculated based on viral titers in panel C and 708 
extracellular core release in panel D. 709 
 710 
Figure 7 711 
Effect of p7 inhibitors on infectivity of HCV/NPHV p7 chimeras. In vitro transcripts of Jc1, 712 
Jc1 p7J6-loop-H14 and Jc1 p7J6-C-ter-H14 were electroporated into Huh-7.5 cells. 4 h post 713 
transfection the respective drug in two different concentrations or DMSO was added. Percentage 714 
of infectivity was calculated by determining the viral titer by TCID50 and normalizing to the 715 
DMSO control. Three independent experiments were performed. Test of the inhibitory effect of 716 
A) Rimantadine (50 µM, 100 µM), B) NN-DGJ (5 µM, 50 µM) and C) NN-DNJ (5 µM, 50 µM]. 717 
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